Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current Assets    
Cash and cash equivalents $ 6,005 $ 15,045
Prepaid expenses and other current assets 657 1,381
Total Current Assets 6,662 16,426
Property and equipment, net 202 367
Right of use asset 316 419
Deposits and other assets 23 23
Total Assets 7,203 17,235
Current Liabilities:    
Accounts payable 992 2,315
Accrued expenses 988 1,776
Accrued employee benefits 752 935
Lease liability 278 249
Total Current Liabilities 3,010 5,275
Lease liability - Long term 261 473
Total Liabilities 3,271 5,748
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding 12,733 12,544
Stockholders' Deficit:    
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 4,146 issued and outstanding and 7,638 issued and outstanding 2,584 4,761
Common Stock, $0.001 par value; 200,000,000 shares authorized, 19,845,283 and 16,808,758 issued and 19,842,955 and 16,806,430 outstanding 20 17
Additional paid-in capital 236,320 232,580
Accumulated deficit (244,975) (235,537)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit (6,051) 1,821
Non-controlling interest (2,750) (2,878)
Total Stockholders' Deficit (8,801) (1,057)
Total Liabilities and Stockholders' Deficit $ 7,203 $ 17,235